Cooperation between NorDiag and Molzym

19-Feb-2010 - Germany

NorDiag and Molzym have now succeeded to combine their respective technologies into an integrated system for automated molecular detection of pathogens, among others for sepsis testing. Following this milestone, the two companies have signed a firm collaboration agreement regarding sale of an integrated solution for sepsis testing and more.

"Short term, this agreement will have a positive effect on the operating income for the Arrow instrument. On a strategic level, collaboration with partners regarding integrated tests opens up a range of opportunities for NorDiag", comments CEO of NorDiag, Mårten Wigstøl.

The system will be launched in Q2-2010. NorDiag's contribution is the Arrow instrument, while Molzym is contributing with reagents. The system will be sold under the brand name of Molzym. NorDiag will distribute on a non exclusive basis the system in North America, and on an exclusive basis in the Nordic countries, while Molzym will sell the system through their distributor network in the rest of the world. The agreement also covers potential agreements with strategic partners. NorDiag and Molzym have agreed upon a fixed split of revenue and profit on revenues from potential strategic partners.

Other news from the department business & finance

Most read news

More news from our other portals

Fighting cancer: latest developments and advances